# ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

> **NCT00615745** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 115 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg

## Key facts

- **NCT ID:** NCT00615745
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2011-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615745, "ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00615745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*